268 related articles for article (PubMed ID: 21338642)
21. Vascular changes in hepatocellular carcinoma.
Yang ZF; Poon RT
Anat Rec (Hoboken); 2008 Jun; 291(6):721-34. PubMed ID: 18484619
[TBL] [Abstract][Full Text] [Related]
22. The molecular mechanism underlying angiogenesis in hepatocellular carcinoma: the imbalance activation of signaling pathways.
Zhao ZC; Zheng SS; Wan YL; Jia CK; Xie HY
Hepatobiliary Pancreat Dis Int; 2003 Nov; 2(4):529-36. PubMed ID: 14627514
[TBL] [Abstract][Full Text] [Related]
23. Differential expression of VEGF isoforms and VEGF(164)-specific receptor neuropilin-1 in the mouse uterus suggests a role for VEGF(164) in vascular permeability and angiogenesis during implantation.
Halder JB; Zhao X; Soker S; Paria BC; Klagsbrun M; Das SK; Dey SK
Genesis; 2000 Mar; 26(3):213-24. PubMed ID: 10705382
[TBL] [Abstract][Full Text] [Related]
24. Overexpression of the neuropilin 1 (NRP1) gene correlated with poor prognosis in human glioma.
Osada H; Tokunaga T; Nishi M; Hatanaka H; Abe Y; Tsugu A; Kijima H; Yamazaki H; Ueyama Y; Nakamura M
Anticancer Res; 2004; 24(2B):547-52. PubMed ID: 15160992
[TBL] [Abstract][Full Text] [Related]
25. Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584.
Liu Y; Poon RT; Li Q; Kok TW; Lau C; Fan ST
Cancer Res; 2005 May; 65(9):3691-9. PubMed ID: 15867364
[TBL] [Abstract][Full Text] [Related]
26. Bone morphogenetic protein 4 is induced in hepatocellular carcinoma by hypoxia and promotes tumour progression.
Maegdefrau U; Amann T; Winklmeier A; Braig S; Schubert T; Weiss TS; Schardt K; Warnecke C; Hellerbrand C; Bosserhoff AK
J Pathol; 2009 Aug; 218(4):520-9. PubMed ID: 19431154
[TBL] [Abstract][Full Text] [Related]
27. Mybl2 expression is under genetic control and contributes to determine a hepatocellular carcinoma susceptible phenotype.
Frau M; Ladu S; Calvisi DF; Simile MM; Bonelli P; Daino L; Tomasi ML; Seddaiu MA; Feo F; Pascale RM
J Hepatol; 2011 Jul; 55(1):111-9. PubMed ID: 21419759
[TBL] [Abstract][Full Text] [Related]
28. Suppression of tumor growth and metastasis by simultaneously blocking vascular endothelial growth factor (VEGF)-A and VEGF-C with a receptor-immunoglobulin fusion protein.
Zhang D; Li B; Shi J; Zhao L; Zhang X; Wang C; Hou S; Qian W; Kou G; Wang H; Guo Y
Cancer Res; 2010 Mar; 70(6):2495-503. PubMed ID: 20197464
[TBL] [Abstract][Full Text] [Related]
29. Accelerated orthotopic hepatocellular carcinomas growth is linked to increased expression of pro-angiogenic and prometastatic factors in murine liver fibrosis.
Kornek M; Raskopf E; Tolba R; Becker U; Klöckner M; Sauerbruch T; Schmitz V
Liver Int; 2008 Apr; 28(4):509-18. PubMed ID: 18339078
[TBL] [Abstract][Full Text] [Related]
30. [Expression of liver-type fatty acid-binding protein and vascular endothelial growth factor and their correlation in human hepatocellular carcinoma].
Dong LH; Li H; Wang F; Li FQ; Zhou HY; Yang HJ
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Mar; 27(3):318-21. PubMed ID: 17425983
[TBL] [Abstract][Full Text] [Related]
31. SPARC and Hevin expression correlate with tumour angiogenesis in hepatocellular carcinoma.
Lau CP; Poon RT; Cheung ST; Yu WC; Fan ST
J Pathol; 2006 Dec; 210(4):459-68. PubMed ID: 17029219
[TBL] [Abstract][Full Text] [Related]
32. Suppression of vascular endothelial growth factor via inactivation of eukaryotic elongation factor 2 by alkaloids in Coptidis rhizome in hepatocellular carcinoma.
Tan HY; Wang N; Tsao SW; Zhang Z; Feng Y
Integr Cancer Ther; 2014 Sep; 13(5):425-34. PubMed ID: 24363282
[TBL] [Abstract][Full Text] [Related]
33. Neuropilin-1 expression by tumor cells promotes tumor angiogenesis and progression.
Miao HQ; Lee P; Lin H; Soker S; Klagsbrun M
FASEB J; 2000 Dec; 14(15):2532-9. PubMed ID: 11099472
[TBL] [Abstract][Full Text] [Related]
34. Hepatitis B x antigen up-regulates vascular endothelial growth factor receptor 3 in hepatocarcinogenesis.
Lian Z; Liu J; Wu M; Wang HY; Arbuthnot P; Kew M; Feitelson MA
Hepatology; 2007 Jun; 45(6):1390-9. PubMed ID: 17539024
[TBL] [Abstract][Full Text] [Related]
35. Vascular density and VEGF expression in hepatic lesions.
Brodsky SV; Mendelev N; Melamed M; Ramaswamy G
J Gastrointestin Liver Dis; 2007 Dec; 16(4):373-7. PubMed ID: 18193117
[TBL] [Abstract][Full Text] [Related]
36. Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver.
El-Assal ON; Yamanoi A; Soda Y; Yamaguchi M; Igarashi M; Yamamoto A; Nabika T; Nagasue N
Hepatology; 1998 Jun; 27(6):1554-62. PubMed ID: 9620326
[TBL] [Abstract][Full Text] [Related]
37. Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma.
Pang R; Poon RT
Cancer Lett; 2006 Oct; 242(2):151-67. PubMed ID: 16564617
[TBL] [Abstract][Full Text] [Related]
38. Rac activation is associated with hepatocellular carcinoma metastasis by up-regulation of vascular endothelial growth factor expression.
Lee TK; Poon RT; Yuen AP; Man K; Yang ZF; Guan XY; Fan ST
Clin Cancer Res; 2006 Sep; 12(17):5082-9. PubMed ID: 16951224
[TBL] [Abstract][Full Text] [Related]
39. Vascular endothelial growth factor tightly regulates in vivo development of murine hepatocellular carcinoma cells.
Yoshiji H; Kuriyama S; Yoshii J; Yamazaki M; Kikukawa M; Tsujinoue H; Nakatani T; Fukui H
Hepatology; 1998 Dec; 28(6):1489-96. PubMed ID: 9828211
[TBL] [Abstract][Full Text] [Related]
40. Effective angiostatic treatment in a murine metastatic and orthotopic hepatoma model.
Raskopf E; Dzienisowicz C; Hilbert T; Rabe C; Leifeld L; Wernert N; Sauerbruch T; Prieto J; Qian C; Caselmann WH; Schmitz V
Hepatology; 2005 Jun; 41(6):1233-40. PubMed ID: 15915456
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
